Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 6
2000 7
2001 16
2002 12
2003 25
2004 18
2005 14
2006 10
2007 10
2008 11
2009 17
2010 23
2011 27
2012 25
2013 34
2014 23
2015 23
2016 11
2017 15
2018 17
2019 15
2020 6
2021 6
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

344 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0% of patients (n=293 of 315) in the dolutegravir, abacavir, and lamivudine group (difference -0.6%, …
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and ten …
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Wohl DA, et al. Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5. Lancet HIV. 2019. PMID: 31068270 Clinical Trial.
We randomly assigned participants (1:1) to receive co-formulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (the bictegravir group) or co-formulated dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg (the dolutegravir group), each with …
We randomly assigned participants (1:1) to receive co-formulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg (t …
Virological efficacy of abacavir: systematic review and meta-analysis.
Cruciani M, Mengoli C, Malena M, Serpelloni G, Parisi SG, Moyle G, Bosco O. Cruciani M, et al. J Antimicrob Chemother. 2014 Dec;69(12):3169-80. doi: 10.1093/jac/dku279. Epub 2014 Jul 28. J Antimicrob Chemother. 2014. PMID: 25074854 Review.
OBJECTIVES: The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. ...CONCLUSIONS: Our cumulative, cross-sectional data suggest a similar virological efficacy of abacavir/lamivudine and tenofovir/emtricitabine regardless of …
OBJECTIVES: The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. ...CONCLUSIONS: Our cumu …
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
Jesson J, Dahourou DL, Renaud F, Penazzato M, Leroy V. Jesson J, et al. Lancet HIV. 2016 Feb;3(2):e64-75. doi: 10.1016/S2352-3018(15)00225-8. Epub 2015 Dec 7. Lancet HIV. 2016. PMID: 26847228 Review.
In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1.08; 95% CI 0.19-6.15), grade 3 or 4 events (0.79 [0.44-1.42]), or death (1.72 [0.77-3.82]) was noted for abacavir relative to non-abacavir regi …
In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1.08; 95% CI 0.19-6 …
Once-daily abacavir in place of twice-daily administration.
Goedken AM, Herman RA. Goedken AM, et al. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1302-8. doi: 10.1345/aph.1E680. Epub 2005 Jun 14. Ann Pharmacother. 2005. PMID: 15956231 Review.
STUDY SELECTION AND DATA EXTRACTION: Publications were included that provided information related to the safety and efficacy of abacavir when used once daily. Preference was given to randomized, double-blind, controlled trials comparing once-daily abacavir regimens …
STUDY SELECTION AND DATA EXTRACTION: Publications were included that provided information related to the safety and efficacy of abacavir
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Shey MS, et al. Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Cochrane Database Syst Rev. 2013. PMID: 23543540 Free PMC article. Review.
OBJECTIVES: To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. ...However, the results showed significant heterogeneity (I(2)=79%); with co-formulated abacavir-l …
OBJECTIVES: To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for i …
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Cruciani M, et al. AIDS. 2011 Oct 23;25(16):1993-2004. doi: 10.1097/QAD.0b013e328349c6ee. AIDS. 2011. PMID: 21716077 Review.
BACKGROUND: The use of abacavir (ABC) has been associated with an increased risk of cardiovascular disease in some cohort studies. ...
BACKGROUND: The use of abacavir (ABC) has been associated with an increased risk of cardiovascular disease in some cohort studies. .. …
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Cruciani M, et al. Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740608 Review.
Several clinical trials have evaluated the efficacy of triple nucleoside combination as a simplification therapy in patients who achieved virologic suppression OBJECTIVES: The aim of this review is to combine randomised, controlled trials to examine whether in patients with undet …
Several clinical trials have evaluated the efficacy of triple nucleoside combination as a simplification therapy in patients who achieved vi …
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis.
Alzate Angel JC, Duque Molina MM, García García HI. Alzate Angel JC, et al. Colomb Med (Cali). 2017 Jun 30;48(2):70-81. Colomb Med (Cali). 2017. PMID: 29021641 Free PMC article. Review.
METHODS: Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). ...
METHODS: Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / …
344 results